Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Sales | 3,047,597 | 2,488,652 | 1,702,177 | 1,032,336 | 580,415 |
| Cost of Goods | 409,539 | 275,119 | 210,460 | 124,512 | 60,987 |
| Gross Profit | 2,638,058 | 2,213,533 | 1,491,717 | 907,824 | 519,428 |
| Operating Expenses | 2,003,447 | 2,090,409 | 1,482,241 | 1,375,215 | 1,212,827 |
| Operating Income | 635,150 | 123,243 | 9,936 | -466,879 | -692,412 |
| Interest Expense | 72,471 | 69,298 | 81,432 | 84,206 | 72,863 |
| Other Income | 37,562 | -69,634 | 4,130 | -6,715 | 30,400 |
| Pre-tax Income | 600,241 | -15,689 | -67,366 | -557,800 | -734,875 |
| Income Tax | -1,486,862 | -107,324 | 16,665 | 30,381 | 6,958 |
| Net Income Continuous | 2,087,103 | 91,635 | -84,031 | -588,181 | -741,833 |
| Net Income Discontinuous | N/A | N/A | N/A | N/A | -912 |
| Minority Interests | -9,793 | -171,849 | 28,021 | -31,847 | -4,190 |
| Net Income | $2,096,896 | $263,484 | $-112,052 | $-556,334 | $-738,555 |
| EPS Basic Total Ops | 8.24 | 1.06 | -0.46 | -2.31 | -3.14 |
| EPS Basic Continuous Ops | 8.21 | 0.37 | -0.34 | -2.44 | -3.14 |
| EPS Diluted Total Ops | 8.09 | 1.04 | -0.46 | -2.31 | -3.14 |
| EPS Diluted Continuous Ops | 8.05 | 0.36 | -0.34 | -2.44 | -3.14 |
| EPS Diluted Before Non-Recurring Items | 2.83 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $707,570 | $184,640 | $71,334 | $-404,536 | $-629,155 |